These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Studies on ras P21 expression and mutation at 12th codon of C-Ha-ras oncogene in squamous cell carcinoma of the larynx].
    Author: Yang Q.
    Journal: Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(4):209-12, 251. PubMed ID: 8167038.
    Abstract:
    Monoclonal antibody directed against the ras oncogene product P21 was used to evaluate P21 expression in 42 cases of tumors of the larynx. The results showed that there was a higher level of ras P21 expression in squamous cell carcinoma of the larynx (LSCC) than in papilloma of the larynx (LP) and the normal tissues adjacent to LSCC, P < 0.05. We had also detected G-->T mutation at codon 12 of Ha-ras oncogenes in LSCC using polymerase chain reaction (PCR). PCR products were hybridized with mutation-specific oligonucleotide probes. Thirty per cent (6/20) LSCC cases harbored this mutation. But G-->T mutation was absent in 3 LP and 5 normal tissues adjacent to LSCC. A relationship may exist between the presence of G-->T mutation and Jakobsson's malignant grading result. All of 6 LSCC cases containing G-->T mutation were in high malignant grading group, P < 0.05. This study implicates that overexpression of ras P21 and presence of Ha-ras G-->T mutation may be one of the molecular mechanisms of maintenance of malignancy and progression of LSCC.
    [Abstract] [Full Text] [Related] [New Search]